>>> GBX +5.7% in pre market on numbers

Greenbrier Comp beats by $0.29, beats on revs; guides Q4 EPS above consensus; guides FY14 EPS above consensus, revs above consensus

Reports Q3 (May) earnings of $1.03 per share, excluding non-recurring items, $0.29 better than the Capital IQ Consensus Estimate of $0.74; revenues rose 36.8% year/year to $593.3 mln vs the $572.4 mln consensus.
Q3 highlights:
  • Revs were up 18.1% sequentially, primarily due to increased deliveries
  • GMs were 16.3%, up from 11.5% in Q2 - Margins were up 480 bps driven by improved efficiencies, pricing and product mix
Backlog/Deliveries/Orders:
  • Railcar backlog as of May 31, 2014 was 26,400 units with an estimated value of $2.75 billion (average unit sale price of $104,000), compared to 15,200 units with an estimated value of $1.54 billion (average unit sale price of $101,000) as of February 28, 2014.
  • New railcar deliveries totaled 4,300 units for the quarter, compared to 3,400 units for the quarter ended February 28, 2014.
  • Orders for 15,600 new railcars valued at $1.65 billion received during the quarter. After quarter end, Greenbrier received orders for an additional 2,700 units valued at approximately $320 million.
  • Marine backlog as of May 31, 2014 totaled approximately $110 million.
Share repurchase update:
Repurchased 352,000 shares of common stock at a cost of $16.0 million during the quarter. To date, repurchased 641,327 shares of common stock at a cost of $26.3 million under a $50 million share repurchase program.

Guidance:
  • Co issues upside guidance for Q4, sees EPS of $0.95-1.05, excluding non-recurring items, vs. $0.87 Capital IQ Consensus Estimate.
  • Co issues upside guidance for FY14, sees EPS of $2.98-3.08, excluding non-recurring items, vs. $2.62 Capital IQ Consensus Estimate
  • Co also sees FY14 revs of over $2.2 bln vs. $2.16 bln Capital IQ Consensus Estimate.
  • Deliveries in the fourth quarter to be between 4,300 units and 4,600 units, resulting in fiscal 2014 deliveries of 15,700 units to 16,000 units

FT : Vix market fear gauge goes global

Wall Street’s ‘fear gauge’ is going global. After success in the US, where betting on share price swings has become firmly established, the Chicago Board Options Exchange is rolling out its Vix equity volatility index into new markets.
Ed Tilly, the exchange’s chief executive, says that, while the CBOE’s main focus is on its home market, it has taken a big step towards making the Vix, which reflects S&P 500 options, the global measure for expectations of market place volatility. It recently expanded trading in futures based on the Vix to 24 hours a day.

“We’ve just begun over the past two years to really ramp up the international story that the global proxy for volatility and uncertainty is the S&P 500’s Vix,” he says.
In September, executives will head to Dublin for the third annual European leg of the risk management conferences it has long used to attract new business in the US.
The proprietary 20-year-old contract is central to the CBOE’s growth. Transaction fees from its Vix and S&P 500 index options contract account for more than half annual revenues.
The Vix looks at the cost of buying a range of options on the S&P 500. When the Vix is low, as it is now, 30-day options are cheap, suggesting there is little demand for protection and investors do not fear disruptive events in the coming month.
But this year it jumped to near its historical average, moving up during Russia’s incursion into Crimea and during periods of uncertainty over the Federal Reserve’s monetary policy. That spurred increased Vix trading, helping CBOE to record first-quarter earnings.

The importance of the Vix among hedge funds and other institutional investors has surged in recent years, buoyed by the popularity of exchange-traded products that are based on it.
Average volumes for options on the Vix are more than 700,000 contracts a day so far this year, nearly triple the rate in 2010, while those in futures on the Vix have soared to 186,000 contracts a day, more than 10 times their 2010 level.
The CBOE launched a London hub last February to capture overseas interest and began extending trading hours in late October after months of delays caused by a software glitch.

Trading during non-US hours now accounts for roughly 7.5 per cent of the CBOE’s futures exchange’s total daily volume, a figure that can double if there is an overnight international incident.
Analysts say the international push will position CBOE well if and when the Vix moves back towards its historical average.
Mr Tilly says: “Our primary focus is domestic,” because many of the institutional investors that are the Vix’s target customers still do not trade the product.
“How do I get the big money behind hedging the gap in their portfolio that is represented by volatility?” he says. “That’s what we spend our time on primarily.”
Vix futures have in recent years also become the basis for a number of ETPs that seek to give investors an easier way to hedge or trade volatility.
Ralph Edwards, a veteran options trader, says that, while the Vix is not perfect, “it’s going to work well enough and by focusing on the deepest and most liquid market for volatility, you probably save yourself from volatility products that are me-too that don’t quite get the job done”.
The strength of its proprietary products has driven speculation that the CBOE will be acquired, possibly by its larger neighbour across town, CME Group.
Mr Tilly says the company must “act in the best interest of our stockholders” but that “there is no for-sale sign around our neck”.
“I would love to find a CBOE out there that has proprietary products, margins over 50 per cent, is lean, controls cost, owns its own technology and has products that are protected by either their own IP or exclusive licenses.”
“That would be a terrific target, something we would look at pretty closely.”

Barrons : 3D Systems: RBC Sees Little In Conference Cancellation, But Stock Shou

Shares of 3-D printer maker 3D Systems (DDD) today closed up $3.66, or 6%, at $63.46, after speculation this morning that the company had canceled a scheduled conference appearance because of some impending material event.

As Bloomberg’s Sarah Rabil and Caitlin McCabe this afternoon wrote, “3D Systems won’t be able to attend a Pacific Crest Securities conference in August because of management scheduling conflicts, according to an e-mail from Stacey Witten, a representative for the company.”

The authors go on to note that analyst Angelo Zino considers the stock as “more of a potential takeover target than we have in a long time.”

Analyst Amit Daryanani with RBC Capital Markets this afternoon reiterates an Outperform rating on the shares, and a $64 price target, writing that he “had the opportunity to check with DDD management regarding recent media reports about 3D Systems canceling from a competitor conference,” and that “our sense is DDD had “tentatively” scheduled to attend the conference and due to management conflict (recall they are going through CFO transition) they elected to not attend the conference.”

And so “While we are surprised by the stock movement today, we do think fundamentals will materially improve in H2:14 that should enable the stock to work higher.”

Daryanani notes that 3D Systems, and Stratasys (SSYS) shares, are working their way back from depressed levels, and he thinks it can continue:

In the last 6 weeks we have seen growth stocks revert back to their 2013 momentum that has enabled growth names along with DDD and SSYS to retrace some of the YTD under-performance. Notably, key momentum indices like SOCL and IBB are up 20% and 19% since May 7th while DDD and SSYS are up 30% and 27% respectively (YTD SOCL -6%, IBB +15%, DDD -29%, SSYS -11%) . We think as long as fundamentals remain constructive, both DDD and SSYS should be able to maintain if not expand their recent share gains. Given the high short interest in both names (DDD at 33% of float and 9.7 days to cover, SSYS at 16% of float, 8 days to cover) we could see continued short squeeze that further drives these names higher.

I would note that Barron’s technical trading guru Michael Kahn penned an item yesterday on the move up in the 3-D stocks in which he writes of DDD, “There is no significant chart resistance until the $80 area.”

Barron's : MannKind Ripe for Profit-Taking After Afrezza Approval

MannKind Ripe for Profit-Taking After Afrezza Approval
The FDA approved the drug maker's inhaled insulin drug, Afrezza. But with shares up 175% since April we'd sell.

Diabetes patients can breathe easier.

The U.S. Food and Drug Administration early Friday approved an inhaled insulin called Afrezza, which frees the drug's manufacturer, MannKind (ticker: MNKD ), to seek a commercial partner. Afrezza works with the two main types of diabetes, which affects about 29 million Americans, roughly a quarter of whom are treated with insulin.

MannKind stock swung sharply during Friday trading before closing down 5.5%. Investors, who have seen shares skyrocket since April, could hardly be blamed for taking money off the table on a cash-burning profitless company. We'd do the same.

Despite the good news, the FDA ordered crucial studies -- and more trials -- to determine long-term cancer, heart and infection risks and if children can use the drug. So MannKind needs a partner fast to launch the drug in early 2015 as hoped.

But attracting a partner will be tricky, especially as MannKind needs one that will facilitate low-cost financing. Moreover, significant risks for the drug remain, and marketing may be more complex than generally thought. Afrezza, for instance, is not suitable for smokers or people with lung ailments.

Tuesday morning, the boutique research firm MLV & Co. downgraded MannKind shares to Hold with an $11 price target, sending shares down 4.5% to $10.47 in afternoon trading.

MLV analyst Graig C. Suvannavejh bases his target on the present value of future cash flows, the first meaningful revenue expected next year and a conservative profit growth rate of 10%.

"In light of the stock's 175% move since early April, we see little reason to move estimates and/or our price target higher on the approval itself," writes Suvannavejh. "We remain optimistic that a high quality partner will sign on, but the proof will be in the pudding."

Suvannavejh says MannKind CEO Al Mann claimed over lunch at a conference in mid-June "that he was already in possession of multiple term sheets" for partners who can help bring the drug to market. Now, more are likely to come.

Of course, Afrezza could grab significant share in the diabetes market. Keith Markey, an analyst at Griffin Securities, sees positives in the FDA decision. By seeking further studies of the drug's impact on children, "the request suggests the FDA thinks the drug will be widely used by pediatric patients and it must be fairly comfortable with the drug's safety profile," writes Markey, who has a Buy rating and a $15 price target.

Moreover with nearly 30% of MannKind's float held by short-sellers, the stock could spring skyward if a rally triggered widespread short-covering.

However, it appears that the easy money has been made. Why get greedy?

Barron's : Contrarian Sentiment Points to Bearish Tilt for Stocks

Contrarian Sentiment Points to Bearish Tilt for Stocks
Contrarian investors are struggling mightily to decide if investors are too optimistic or too worried.

Is there too much bullishness right now on Wall Street—or too much pessimism?

A lot is riding on the answer, if you—like the majority of the investment advisors I monitor—have contrarian instincts. As contrarians are fond of saying, the market likes to "climb a wall of worry." Therefore, it would be a bad sign if there were too much bullishness—and vice versa.

Unfortunately, there is nothing even closely resembling a consensus about the nature of the prevailing mood. Some of the advisors I monitor are sure that Wall Street has been possessed by nothing short of irrational exuberance, while others are amazed by high perceived pessimism.

To give two recent examples: Hedge-fund manager Doug Kass, president of Seabreeze Partners Management, for example, says we're seeing a "bull market in complacency;" while Michael Purves, chief global strategist at Weeden & Co., terms the prevailing mood a "wall of hatred."

If there is any agreement between these otherwise diametrically opposed points of view, it's that contrarian analysis is worth paying attention to—that the market tends to do the opposite of what the majority thinks it will. And it makes intuitive sense that it would.

After all, it's human nature to become more optimistic as the market rises and more pessimistic as it declines. From this simple truism it follows that optimism will be at its all-time high right at bull-market peaks—just as bear markets begin. The opposite will be the case at market bottoms.

Putting this intuition into practice is another thing entirely; however, as is well illustrated by the wide disagreement about today's prevailing sentiment. In my experience of tracking hundreds of investment newsletters for over three decades, assessments of sentiment often lie in the eye of the beholder.

All too often, the bulls who are eager to wrap themselves in the flag of contrarian analysis will see a "wall of worry" everywhere—just as the bears will be inclined to detect too much bullishness.

For the record, I am not accusing either Mr. Kass or Mr. Purves of this behavior. But it is clear that, in order to resurrect contrarian analysis from subjectivity, it's incumbent that we focus on objective measures of sentiment.

I have rigorously analyzed a dozen different sentiment measures, and only three met econometric tests of statistical significance. Each is based on the behavior of retail investors or retail-oriented advisors:

• The well-known survey of newsletter sentiment that has been conducted weekly since 1963 by Investors Intelligence. The survey places each newsletter in one of three categories: Outright bullish on the stock market, outright bearish, or long-term bullish but expecting a shorter-term correction.

• The second sentiment survey I analyzed was the one maintained by the American Association of Individual Investors. This organization's members that come to its Website are asked to indicate whether they are bullish, bearish, or neutral on the stock market. Weekly totals have been maintained since 1987.

• The third sentiment survey on which I focused was the one maintained by the Hulbert Financial Digest (HFD). It reflects the average recommended equity exposure among a subset of short-term stock-market timers who are monitored by the HFD (as represented by the Hulbert Stock Newsletter Sentiment Index, or HSNSI).

Unfortunately, all three measures show that we're far closer to the "optimism" end of the spectrum. And that's bearish from a contrarian point of view.

Consider in particular the message painted by the HSNSI, which currently stands at 63.2%. Though that's lower than the highest level this index has ever reached—which is 82.3%—it nevertheless is far higher than the norm. Over the last five years, for example, the HSNSI has averaged 38.7%.

Since 1985, which is how far back HSNSI data extend, the Wilshire 5000 has fallen an average of 3.1% over the four weeks following HSNSI levels greater than or equal to 60% -- and 6.9% over the subsequent 13 weeks.

To be sure, bullishness has been high for quite some time, and so far at least the market has defied these historical odds. But, unless you think the market's relationship to human psychology has fundamentally changed, it would seem risky indeed to bet that the bull market will continue a lot higher in the face of this high level of bullishness.

One measure of that risk: The HSNSI was also high for an equally long time prior to the 1987 Crash, for example, as well as a number of months in the summer of 1998 prior to the market's meltdown that accompanied the collapse of Long Term Capital Management.

Ned Davis, the founder of Ned Davis Research, who for several decades has also closely studied sentiment indicators, suspects that the Federal Reserve's easy money policy has played a major role in keeping the market going despite sentiment levels that normally would presage a correction. He furthermore reminds us that, even when sentiment peaks correctly presage market tops, they often can be early.

All things considered, for now he remains "neutral to mildly bullish."

But it also seems clear that market risk is high right now. As Davis also acknowledges, the sentiment data lead him to "think another 1987-type correction is possible."

(NYPost) GoPro shares jump 100 percent in less than 5 days

That was quick.
Shares of red hot GoPro more than doubled less than five days after the lightweight digital movie camera maker went public.
The impressive 100 percent jump was realized Tuesday afternoon when shares crossed the $48 mark toward an intraday high of $49.76 a share.
GoPro shares closed Tuesday at $48.80, up 20.4 percent.
They debuted on Nasdaq on June 25 after being priced at $24 the previous evening.
So far this year, GoPro, whose cameras are designed primarily for people partaking in sports and outdoor activities, has produced the 7th highest price gain of any 2014 initial public offering.
In fact, only two other IPO’s this year have doubled their share price within five days of being on the market.
GoPro’s astronomical rise has also doubled the net worth of GoPro founder and CEO Nicholas Woodman — adding a cool $1.2 billion to his personal wealth in a week.
Woodman is now worth north of $2.5 billion.
Meanwhile, Woodman’s father, who provided seed capital of $200,000 when the company started, is now a multi-millionaire; his stake in the company is now estimated to be around $280 million.
Some on Wall Street remain cautious in the wake of GoPro’s fast break from the gate.
Charlie Anderson, an analyst at Dougherty & Co, is wary of GoPro’s better-than-expected performance, believing euphoric trading is the root cause behind GoPro’s heady $6 billion valuation.
To be sure, the small supply of shares floated in the IPO is also helping create a positive supply-demand ratio.
Only 17.8 million of GoPro’s 123 million shares were on offer during its debut.
Investors who missed out on the IPO have driven the price higher since it debuted by continuing to buy available shares.
GoPro was the No. 1 camcorder seller in the US last year, cornering nearly 45% of the market. Since 2004, it has sold more than 8.5 million cameras, while its revenue more than quadrupled between 2011 and 2013.

(UBS) US Pharma : 2Q14 Preview: Still Bullish on M&A Theme

* What’s new? 3 stocks with notable upside to consensus for 2Q
For MNK, we are 18% above consensus and believe owning the stock even if for just
the qtr makes sense. We also see upside from IPXL (33%) and TEVA (6%) but believe
the buy-side is ahead of the sell-side for these beats. We are also 2% above the Street
for ACT, and if anything we may be too conservative with our estimate. JAZZ is the
one stock where we are slightly above consensus (3%) and think Street numbers
should probably come down some. Our preview includes our updated financial models,
company milestones, and price increases for key products as well as industry valuation
models. Changes to our EPS estimates and price targets are presented in Figure 4.

* In generics, ACT remains our favorite but we also like MYL and PRGO
Actavis is a strong earnings story, and we believe sustainable double digit growth for
the next 3-5 years is still underappreciated. We also expect M&A to play an important
part of the story. In Mylan, we see continued double-digit growth driven by multiple
growth opportunities (injectables, Copaxone, Advair, and biosimilars) and we also
expect M&A to augment that growth. For Perrigo, we continue to believe the macro
drivers of increased private label penetration and Rx to OTC switches will remain
strong, and we expect mgt to leverage its lower tax rate from Elan to do further deals.

* Many opportunities in spec: We like MNK, VRX, ENDP, and JAZZ
MNK is our top pick, and we believe the Questcor deal is transformational and highly
accretive. On Valeant, whether it gets Allergan or not, we expect Valeant as well as
Endo to do accretive deals that should move the stocks. Now that Allergan has started
to let the numbers loose, it is an even stronger growth story and performer. In Jazz, we
still believe in its sustainable strong growth and the strength of the Xyrem IP.

* In large-cap: Our focus remains on MRK and PFE
We believe sentiment continues to get better on Merck for a new product story (PD-1,
HCV, maybe even Odanacatib/Suvorexant). Our thoughts on Pfizer are similar with
new products like Palbo and PCSK9 and many Phase 2 readouts over the next year as
well as the likelihood of eventually unlocking further value with a company breakup.